v3.26.3
Reportable Segment Information
12 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Reportable Segment Information

NOTE Q – REPORTABLE SEGMENT INFORMATION

Ashland determines its reportable segments based on how operations are managed internally for the products and services sold to customers, including how the results are reviewed by Guillermo Novo, Chair and Chief Executive Officer of the Company, which includes determining resource allocation methodologies used for reportable segments. EBITDA is the primary measures of performance that are reviewed by the chief operating decision maker in assessing each reportable segment's financial performance. Ashland does not aggregate operating segments to arrive at these reportable segments.

Reportable segment business descriptions

Life Sciences is composed of pharmaceuticals, nutrition, agricultural chemicals, diagnostic films (formerly known as advanced materials) and fine chemicals. Pharmaceutical solutions include controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers and tablet binders. Nutrition solutions include thickeners, stabilizers, emulsifiers and additives for enhancing mouthfeel, controlling moisture migration, reducing oil uptake and binding structured foods. Customers include pharmaceutical, food and beverage manufacturers, hospitals and radiologists. The nutraceuticals business was sold in August 2024. See Note B for additional details.

Personal Care is composed of biofunctionals, microbial protectants (preservatives), skin care, sun care, oral care, hair care and household solutions. These businesses have a broad range of natural, nature-derived, biodegradable, and high-performance ingredients for customer-driven solutions to help protect, renew, moisturize and revitalize skin and hair, and provide solutions for toothpastes, mouth washes and rinses, denture cleaning and care for teeth. Personal Care supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers for household, industrial and institutional cleaning products. Customers include formulators at large multinational branded consumer products companies and smaller, independent boutique companies. The Avoca business was sold in March 2025. See Note B for additional details.

Specialty Additives is composed of rheology and performance-enhancing additives serving the architectural coatings, construction, energy, automotive and various industrial markets. Solutions include coatings additives for architectural paints, finishes and lacquers, cement- and gypsum-based dry mortars, ready-mixed joint compounds, synthetic plasters for commercial and residential construction, and specialty materials for industrial applications. Products include rheology modifiers (cellulosic and associative thickeners), foam control agents, surfactants and wetting agents, pH neutralizers and environmental filters, ingredients that aid the manufacturing process of ceramic capacitors, advanced ceramics used in catalytic converters, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals and alloys for welding. Products help improve desired functional outcomes through rheology modification and control, water retention, workability, adhesive strength, binding power, film formation, deposition and suspension and emulsification. Customers

include, but are not limited to, global paint manufacturers, electronics and automotive manufacturers, textile mills, the construction industry and welders.

Intermediates is composed of the production of 1,4 butanediol ("BDO") and related derivatives, including n-methylpyrrolidone. These products are used as chemical intermediates in the production of engineering polymers and polyurethanes, and as specialty process solvents in a wide array of applications including electronics, agriculture, pharmaceuticals, water filtration membranes and more. BDO is also supplied to Life Sciences, Personal Care, and Specialty Additives for use as a raw material.

Unallocated and other generally includes items such as certain significant company-wide restructuring activities, corporate governance costs and legacy costs or activities that relate to divested businesses that are no longer operated by Ashland.

International data

Information about Ashland’s domestic and international operations for the years ended September 30, are as follows. Ashland has no operations in any individual international country or single customer that represented more than 10% of sales during the years ended September 30, 2026, 2025 and 2024.

 

 

Sales to external
customers

 

 

Net assets
(liabilities)

 

 

Property, plant and
equipment - net

 

(In millions)

 

2026

 

 

2025

 

 

2024

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

United States

 

$

462

 

 

$

464

 

 

$

624

 

 

$

720

 

 

$

872

 

 

$

789

 

 

$

848

 

International

 

 

1,401

 

 

 

1,360

 

 

 

1,489

 

 

 

1,128

 

 

 

1,032

 

 

 

345

 

 

 

353

 

 

 

$

1,863

 

 

$

1,824

 

 

$

2,113

 

 

$

1,848

 

 

$

1,904

 

 

$

1,134

 

 

$

1,201

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reportable segment results

Results of Ashland’s reportable segments are presented based on its management and internal accounting structure. The structure is specific to Ashland; therefore, the financial results of Ashland’s reportable segments are not necessarily comparable with similar information for other comparable companies. Ashland allocates all costs to its reportable segments except for certain significant company-wide restructuring activities, certain corporate governance costs and other costs or activities that relate to former businesses that Ashland no longer operates. The service cost component of pension and other postretirement benefits costs is allocated to each reportable segment on a ratable basis; while the remaining components of pension and other postretirement benefits costs are recorded within the other net periodic benefit (income) loss caption of the Statements of Consolidated Comprehensive Income (loss). Ashland refines its expense allocation methodologies to the reportable segments from time to time as more refined information becomes available and the industry or market changes. Significant revisions to Ashland’s methodologies are adjusted for all reportable segments on a retrospective basis. There were no material changes in methodology for the years ended September 30, 2026, 2025 or 2024.

Ashland determined that disclosing sales by specific product was impracticable due to the highly customized and extensive portfolio of products offered to customers and since no one product or a small group of products could be aggregated together to represent a majority of revenue within a reportable segment.

The following table presents various financial information for each reportable segment for the years ended September 30:

 

(In millions)

 

2026

 

 

2025

 

 

2024

 

Sales

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

671

 

 

$

641

 

 

$

810

 

Personal Care

 

 

592

 

 

 

577

 

 

 

634

 

Specialty Additives

 

 

504

 

 

 

511

 

 

 

572

 

Intermediates

 

 

135

 

 

 

137

 

 

 

144

 

Intersegment sales(a)

 

 

(39

)

 

 

(42

)

 

 

(47

)

 

 

$

1,863

 

 

$

1,824

 

 

$

2,113

 

Cost of sales

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

411

 

 

$

418

 

 

$

515

 

Personal Care

 

 

350

 

 

 

345

 

 

 

398

 

Specialty Additives

 

 

423

 

 

 

433

 

 

 

522

 

Intermediates

 

 

117

 

 

 

121

 

 

 

107

 

Intersegment sales

 

 

(39

)

 

 

(42

)

 

 

(47

)

 

 

$

1,262

 

 

$

1,275

 

 

$

1,495

 

Selling, general and administrative expense

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

97

 

 

$

77

 

 

$

89

 

Personal Care

 

 

87

 

 

 

84

 

 

 

95

 

Specialty Additives

 

 

70

 

 

 

64

 

 

 

61

 

Intermediates

 

 

6

 

 

 

7

 

 

 

7

 

   Total operating segments

 

 

260

 

 

 

232

 

 

 

252

 

Unallocated and other

 

 

117

 

 

 

112

 

 

 

152

 

 

 

$

377

 

 

$

344

 

 

$

404

 

Research and development expense

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

14

 

 

$

15

 

 

$

15

 

Personal Care

 

 

23

 

 

 

25

 

 

 

26

 

Specialty Additives

 

 

14

 

 

 

12

 

 

 

11

 

Intermediates

 

 

—

 

 

 

—

 

 

 

—

 

   Total operating segments

 

 

51

 

 

 

52

 

 

 

52

 

Unallocated and other

 

 

4

 

 

 

2

 

 

 

3

 

 

 

$

55

 

 

$

54

 

 

$

55

 

Intangibles amortization expense

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

18

 

 

$

18

 

 

$

23

 

Personal Care

 

 

32

 

 

 

35

 

 

 

43

 

Specialty Additives

 

 

9

 

 

 

9

 

 

 

10

 

Intermediates

 

 

1

 

 

 

1

 

 

 

—

 

 

 

$

60

 

 

$

63

 

 

$

76

 

Equity and other income

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

—

 

 

$

—

 

 

$

—

 

Personal Care

 

 

1

 

 

 

1

 

 

 

—

 

Specialty Additives

 

 

—

 

 

 

—

 

 

 

—

 

Intermediates

 

 

—

 

 

 

—

 

 

 

—

 

   Total operating segments

 

 

1

 

 

 

1

 

 

 

—

 

Unallocated and other

 

 

3

 

 

 

3

 

 

 

6

 

 

 

$

4

 

 

$

4

 

 

$

6

 

 

 

 

 

 

 

 

 

 

 

 

 

(In millions)

 

2026

 

 

2025

 

 

2024

 

Goodwill impairment and loss on divestitures, net

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

—

 

 

$

375

 

 

$

—

 

Personal Care

 

 

—

 

 

 

—

 

 

 

—

 

Specialty Additives

 

 

—

 

 

 

331

 

 

 

—

 

Intermediates

 

 

—

 

 

 

—

 

 

 

—

 

   Total operating segments

 

 

—

 

 

 

706

 

 

 

—

 

Unallocated and other

 

 

8

 

 

 

161

 

 

 

115

 

 

 

$

8

 

 

$

867

 

 

$

115

 

Operating income (loss)

 

 

 

 

 

 

 

 

 

Life Sciences(b)

 

$

131

 

 

$

(262

)

 

$

168

 

Personal Care(c)

 

 

101

 

 

 

90

 

 

 

73

 

Specialty Additives(d)

 

 

(12

)

 

 

(338

)

 

 

(32

)

Intermediates

 

 

11

 

 

 

8

 

 

 

29

 

   Total operating segments

 

 

231

 

 

 

(502

)

 

 

238

 

Unallocated and other(e)

 

 

(126

)

 

 

(273

)

 

 

(264

)

   Total operating income (loss)

 

$

105

 

 

$

(775

)

 

$

(26

)

Net interest and other expense (income)

 

 

40

 

 

 

33

 

 

 

(24

)

Other net periodic benefit (income) loss

 

 

(4

)

 

 

1

 

 

 

22

 

Income (loss) from continuing operations before income taxes

 

$

69

 

 

$

(809

)

 

$

(24

)

 

 

 

 

 

 

 

 

 

 

EBITDA(f)

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

187

 

 

$

(187

)

 

$

229

 

Personal Care

 

 

161

 

 

 

155

 

 

 

152

 

Specialty Additives

 

 

51

 

 

 

(254

)

 

 

89

 

Intermediates

 

 

16

 

 

 

21

 

 

 

42

 

   Total operating segments

 

 

415

 

 

 

(265

)

 

 

512

 

Unallocated and other

 

 

(125

)

 

 

(273

)

 

 

(264

)

   Total EBITDA

 

$

290

 

 

$

(538

)

 

$

248

 

Depreciation expense

 

 

125

 

 

 

174

 

 

 

198

 

Amortization expense

 

 

60

 

 

 

63

 

 

 

76

 

Net interest and other expense (income)

 

 

40

 

 

 

33

 

 

 

(24

)

Other net periodic benefit (income) loss

 

 

(4

)

 

 

1

 

 

 

22

 

Income (loss) from continuing operations before income taxes

 

$

69

 

 

$

(809

)

 

$

(24

)

 

 

 

 

 

 

 

 

 

 

Depreciation expense

 

 

 

 

 

 

 

 

 

Life Sciences(g)

 

$

38

 

 

$

57

 

 

$

38

 

Personal Care(h)

 

 

28

 

 

 

30

 

 

 

36

 

Specialty Additives(i)

 

 

54

 

 

 

75

 

 

 

111

 

Intermediates

 

 

4

 

 

 

12

 

 

 

13

 

   Total operating segments

 

 

124

 

 

 

174

 

 

 

198

 

Unallocated and other(j)

 

 

1

 

 

 

—

 

 

 

—

 

 

 

$

125

 

 

$

174

 

 

$

198

 

 

 

 

 

 

 

 

 

 

 

 

(In millions)

 

2026

 

 

2025

 

 

2024

 

Additions to property, plant and equipment

 

 

 

 

 

 

 

 

 

Life Sciences

 

$

31

 

 

$

49

 

 

$

61

 

Personal Care

 

 

9

 

 

 

7

 

 

 

11

 

Specialty Additives

 

 

42

 

 

 

34

 

 

 

61

 

Intermediates

 

 

4

 

 

 

3

 

 

 

2

 

Unallocated and other

 

 

2

 

 

 

5

 

 

 

2

 

 

 

$

88

 

 

$

98

 

 

$

137

 

 

 

 

 

 

 

 

 

 

 

 

(In millions)

 

2026

 

 

2025

 

Assets

 

 

 

 

 

 

Life Sciences

 

$

1,422

 

 

$

1,498

 

Personal Care

 

 

701

 

 

 

751

 

Specialty Additives

 

 

964

 

 

 

1,020

 

Intermediates

 

 

116

 

 

 

116

 

Unallocated and other

 

 

1,324

 

 

 

1,226

 

 

 

$

4,527

 

 

$

4,611

 

Property, plant and equipment - net

 

 

 

 

 

 

Life Sciences

 

$

440

 

 

$

481

 

Personal Care

 

 

106

 

 

 

101

 

Specialty Additives

 

 

463

 

 

 

484

 

Intermediates

 

 

31

 

 

 

30

 

Unallocated and other

 

 

94

 

 

 

105

 

 

 

$

1,134

 

 

$

1,201

 

 

 

 

 

 

 

 

(a)
Intersegment sales from Intermediates are accounted for at prices that approximate market value. All other intersegment sales are accounted for at cost.
(b)
Includes $16 million of capital projects impairment charges in 2026 and goodwill impairment of $375 million for Life Sciences in 2025.
(c)
Includes capital projects impairment charge of $11 million for Personal Care in 2024.
(d)
Includes $2 million of capital projects impairment charges in 2026 and goodwill impairment of $331 million for Specialty Additives in 2025.
(e)
Includes a $3 million gain on sale of excess corporate properties, a $2 million excess land contract termination fee income and a $13 million Argentina foreign currency cumulative translation adjustment in 2026, $8 million gain on sale and a $183 million impairment charge related to the divestiture of the Avoca business in 2025, and a $8 million loss on sale and a $99 million impairment charge related to the divestiture of the Nutraceuticals business in 2024 within the loss on divestitures, net.
(f)
Excludes loss from discontinued operations, net of income taxes and other net periodic benefit (income) loss. See the Statements of Consolidated Comprehensive Income (Loss) for applicable amounts excluded.
(g)
Depreciation includes accelerated depreciation of $21 million for Life Sciences in 2025.
(h)
Depreciation includes accelerated depreciation of $1 million, $1 million and $2 million for Personal Care in 2026, 2025 and 2024, respectively.
(i)
Depreciation includes accelerated depreciation of $3 million, $19 million and $55 million for Specialty Additives in 2026, 2025 and 2024, respectively.
(j)
Depreciation includes accelerated depreciation of $1 million for Unallocated and other in 2026.